Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms PSMA BiTE Antibody, AMG-212, BAY-2010112 + [1] |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 1 | United States | 12 Feb 2018 | |
Castration-Resistant Prostatic Cancer | Phase 1 | Austria | 02 Nov 2012 | |
Castration-Resistant Prostatic Cancer | Phase 1 | Germany | 02 Nov 2012 |
Phase 1 | 47 | ieyaajdtcq(omjovojlsf) = oraaqixkhp zdssphcffn (ciiknxlyfo ) | - | 01 Feb 2021 |